Watch these videos to see how the features of the MAGNAIR device may fit into your patients’ daily lives. Whether your patients are at home with the grandkids, on vacation, or spending quiet time at the library, the following LONHALA MAGNAIR device features may help them enjoy the things they love.
Administration takes 2-3 minutes twice daily, with proper assembly and cleaning. Improper cleaning and maintenance may increase administration time.1,2
It is important for patients to understand how to correctly administer LONHALA vials using MAGNAIR. Instruct patients that LONHALA vials should only be administered via MAGNAIR, and MAGNAIR should not be used for administering other medications.
Its small, light, and compact design allows it to fit in a discreet carrying bag2
Virtually silent administration allows patients to administer medication without noticeable noise.3,4
Patients breathe regularly through the mouthpiece when taking treatment1,3
Patients should be instructed to:
1. LONHALA MAGNAIR (glycopyrrolate) Inhalation Solution [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.
2. LONHALA MAGNAIR (glycopyrrolate) Inhalation Solution [instructions for use]. Marlborough, MA: Sunovion Pharmaceuticals Inc.
3. Pham S, Ferguson GT, Kerwin E, Goodin T, Wheeler A, Bauer A. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. [published online ahead of print Nov 10, 2017]. J Aerosol Med Pulm Drug Deliv. Doi:10.1089/jamp.2017.1384
4. Data on file. eLete Loudness measurement. Test Report 4669, 2017. PARI Pharma GmbH.
LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.
LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.
As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.
Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.
LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.
The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).
LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.